Audentes Therapeutics Garners $65,000,000 Series C Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8acefdf4-1452-4b06-a85d-2c80b8782450 - Date
10/14/2015 - Company Name
Audentes Therapeutics - Mailing Address
101 Montgomery Street. San Francisco, CA 94104 USA - Company Description
Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology. - Website
http://www.audentestx.com - Transaction Type
Venture Equity - Transaction Amount
$65,000,000 - Transaction Round
Series C - Proceeds Purposes
The proceeds from the Series C financing will be primarily used to advance the company’s three lead development programs to key clinical milestones and to establish internal GMP manufacturing capabilities. - M&A Terms
- Venture Investor
Sofinnova Ventures - Venture Investor
Redmile Group - Venture Investor
RA Capital - Venture Investor
T. Rowe Price - Venture Investor
Rock Springs Capital - Venture Investor
Cormorant Asset Management - Venture Investor
Cowen Capital Partners - Venture Investor
Foresite Capital - Venture Investor
OrbiMed - Venture Investor
5AM Ventures - Venture Investor
Versant Ventures - Venture Investor
Deerfield Capital - Venture Investor
Venrock
